一个改进的生物标志物引导的适应性患者丰富设计用于瘤学试验
Zhenwei Zhou1, Zhaoyang Teng2, Jian Zhu2
1Amgen, Global Biostatistical Science, Thousand Oaks, CA, USA.
Journal of biopharmaceutical statistics
|April 23, 2025
概括
这项研究引入了一种改进的生物标志物引导的适应性丰富设计,用于瘤学试验. 它通过允许动态决策和样本大小调整来提高效率和力量,优化特定患者群体的治疗识别.
科学领域:
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
- 在瘤学瘤学.
背景情况:
- 生物标志物引导的适应性丰富设计提高了瘤学试验的效率.
- 当前的设计可能在临时决策和样本大小重新估计方面缺乏灵活性.
- 优化治疗识别需要适应性策略,以适应异质患者群体.
研究的目的:
- 为瘤学试验提出一个改进的生物标志物引导的适应性丰富设计.
- 提高临时决策和样本大小重新估计的灵活性.
- 提高在特定人群中识别有效治疗的效率和能力.
主要方法:
- 开发了一个具有灵活的临时决策规则的动态适应性丰富设计.
- 在生物标志物阳性和整体人群中,结合了早期停止的有效性或徒劳性.
- 使用改进的条件功率方法实施了样本大小的重新估计.
主要成果:
- 拟议的设计保持了对I型错误的强有力的控制.
- 实现了高的统计能力和正确的临时决策的高概率.
- 当治疗对生物标志物阳性或整体人群有益时,已证明有效.
结论:
- 新的框架为瘤学试验提供了更灵活,更有效的方法.
- 确保在试验期间动态选择适当的患者群体.
- 改善了对异质患者群体有效治疗方法的识别.
更多相关视频
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
16.3K
07:34Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
584
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Survival Analysis
298
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
298
